PKC activators and combinations thereof
The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
1. A method for treating Alzheimer's disease or Parkinson's disease comprising administering to a patient in need thereof a cyclopropanated PUFA-cholesterol conjugate and retinoic acid, wherein the cyclopropanated PUFA-cholesterol conjugate is selected from:
2. A method for treating Alzheimer's disease or Parkinson's disease comprising administering to a patient in need thereof a cyclopropanated PUFA-cholesterol conjugate and at least one retinoid, wherein the cyclopropanated PUFA-cholesterol conjugate is selected from:
3. The method according to claim 2 , wherein the at least one retinoid is chosen from retinoic acid, N-(4-hydroxyphenyl) retinamide (“4-HPR”), 4-(5, 5, 8, 8-Tetramethyl-5, 6, 7, 8-tetrahydronaphthalen-2-ylethynyl) benzoic acid (“ec23”), 9-cis retinoic acid, 13-cis retinoic acid, all-trans-4-hydroxyretinoic acid, all-trans-4-oxoretinoic acid, 3,4, didehydroretinoic acid, retinol, retroretinol, all-trans-4-hydroxyretinol, all-trans-4-oxoretinol, 14-hydroxy-4, 14-retroretinol, retinaldehyde, lycopene, apo-1 0′-lycopenoic acid, and acycloretinoic acid.
4. The method according to claim 2 , wherein the at least one retinoid is retinoic acid.
5. The method according to claim 2 , wherein the at least one retinoid is administered to a patient in need thereof before administration of the at least one cyclopropanated PUFA-cholesterol conjugate.
6. The method according to claim 2 , wherein the at least one retinoid is administered to a patient in need thereof after administration of the cyclopropanated PUFA-cholesterol conjugate.
7. The method according to claim 2 , wherein the at least one retinoid and the cyclopropanated PUFA-cholesterol conjugate are administered simultaneously.